Dulaglutide, semaglutide, and tirzepatide exhibit comparable gastrointestinal adverse event risk
1. In this cohort study, dulaglutide, semaglutide, and tirzepatide demonstrated similar risks of gastrointestinal adverse events (AEs) in…
Weight-loss drugs: From a trickle to a flood
It’s been varyingly called the “fat shot”, “skinny jab” or “magic pill” by politicians and celebrities who’ve put…
Loss of Appetite May Result in Loss of Margins for Swiggy, Zomato – outlookbusiness.com
Loss of Appetite May Result in Loss of Margins for Swiggy, Zomato outlookbusiness.com The discovery that launched a new…
Ozempic vs Mounjaro vs Wegovy: Prices in India vs US and what the research actually shows
Ozempic, Mounjaro, Wegovy: Guide to Weight Loss Injections and Their Cost in India vs US Ozempic, Mounjaro and…
Prices of Ozempic vs Mounjaro vs Wegovy: How much they cost in the US, UK, India and around the world |
Groundbreaking diabetes and weight loss drugs like Ozempic and Mounjaro are transforming treatment, offering significant weight loss. However,…
Karan Johar’s Ozempic joke: What you ought to know about weight loss drug
Ozempic 101: Is it behind Karan Johar’s weight loss? Fact sheet for health enthusiasts on benefits and risks…
Ozempic coming soon to India: What is it? Benefits, side effects and controversies
India’s drug controller, the Central Drugs Standard Control Organisation (CDSCO), approved Ozempic (semaglutide) on 26 September for use…
Wegovy And Zepbound Cost Effective But They Could Break Drug Budgets
The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative…
Pricing group says weight-loss drugs becoming more cost-effective
By Deena Beasley (Reuters) -An influential drug pricing watchdog on Tuesday said popular GLP-1 weight-loss injections have become…
GLP-1 drugs and vision loss: How significant are the risks? – Medical News Today
GLP-1 drugs and vision loss: How significant are the risks? Medical News Today From stomach paralysis to vision loss:…